Medikamentöse Therapie der Endometriose mit GnRH-Antagonisten

W. Küpker, R. Felberbaum, Eduard Malik, K. Diedrich
In: Der Gynäkologe · 2002 · vol. 35(3) , pp. 243–249 · doi:10.1007/s00129-002-1176-6 · W1997052447
article OA: closed CC0 ⤵ 4 in-corpus citations
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View at publisher → View on OpenAlex
⚙ AI-generated summary by claude@2026-06+body, 2026-06-07 ⓘ

This pilot study examined a GnRH antagonist for endometriosis, finding complete symptom relief, no estrogen withdrawal symptoms, and improved disease stage without affecting regression at basal estrogen levels.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-07 ⓘ

The paper investigates whether a GnRH antagonist (Cetrotide®) can be used for medical treatment of symptomatic endometriosis, focusing on symptom control and endometriosis regression while limiting estrogen-withdrawal side effects. In a pilot study of women treated after primary diagnostic laparoscopy, all participants reported complete relief of complaints without typical estrogen-deprivation symptoms, and second-look laparoscopy showed improved endometriosis stage in all cases except those with stage IV (ASRM). A sequential regimen of Cetrotide® 3 mg once weekly for 8 weeks is presented as an alternative approach, with the caveat that regression appears unaffected only when baseline estrogen levels are preserved and that metabolic changes require further study. This paper is centrally about endometriosis — it evaluates sequential GnRH antagonist therapy (Cetrotide®) for symptom relief and disease stage changes observed on second-look laparoscopy.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

My notes (saved in your browser only)

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (21)

Cited by (4)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
unpaywall
last seen: 2026-06-02T02:00:03.124865+00:00
License: CC0 · commercial use OK